- Heart failure
- Hypertension and drug resistant hypertension
- Dyspnea
- Pacemaker optimization
- Fluid assessment
Warranty
We are so confident in our products that we offer a one-year warranty on all of our ICG systems.
DID YOU KNOW?
ICG results are available within a few minutes, allowing more rapid patient evaluation than that afforded by radiographic or laboratory studies.
Sales help
Talk To Us Questions? Comments? Opinions? We want to hear from you.
Tell Us More
BioZ DX Details
Reliable and Accurate Cardiovascular Health Analysis
The BioZ DX® Diagnostics system allows you to rapidly and noninvasively evaluate a patient's cardiovascular health, including cardiac output, systemic vascular resistance, contractility, and fluid status. The BioZ DX produces a comparison status report so you can compare a patient's previous impedance cardiography (ICG) report with the current ICG report, helping you to identify whether a patient responded to therapy or if heart function has changed. This information is critical when evaluating a patient's cardiovascular health and risk of developing complications due to pre-existing cardiovascular issues, including hypertension, heart failure, and dyspnea.The BioZ DX is only available in the United States. For international customers, please visit www.medis-de.com.
Applications
BioZ DX Applications Include:
What Our Customers Say
"Clinicians are coming full-circle and returning to viewing heart failure as a hemodynamic (blood flow) disease. It is the clinicians' responsibility to become familiar with ICG technology, its applications, and its proven role in clinical decision-making and treatment."
William T. Abraham, MD
FACP, FACC, Chief of Cardiovascular Medicine and Co-Director of Gill Heart Institute, University of Kentucky College of Medicine
"The BioZ's noninvasive ICG measurements reduce and can virtually eliminate the need for an invasive PAC measurement and are invaluable in patients undergoing inotropic infusion therapy. The study highlights the importance of ICG data in optimizing patient care, which translates into improved patient functional status, decreased emergency room visits, and reduced hospitalizations during short and long-term follow-up (previously published data). ICG technology is fast becoming a necessity in treating heart failure patients."
Comment from, "CardioDynamics' Technology Demonstrates Predictive Power for Clinical Status and Outcomes in Heart Failure Patients, 2000, PRNewswire
Mary Anne Papp, MD
Director, Heart Failure Program, Michael Reese Hospital
“In our clinic, the use of monitoring with ICG has become a standard of care. For over three years, we have used this vital data to assist our physicians and nurses to fine-tune the pharmacologic and fluid management of hypertensive patients and those with heart failure. This new 'informed' approach to treatment is key in improving outcomes for the millions affected by high blood pressure, heart failure, and other cardiovascular diseases.”
Comment from, “CardioDynamics Announces Four Significant BioZ Studies Demonstrating Improved Patient Outcomes, Reduced Length of Hospital Stay, and Decreased Costs,” 2000, BusinessWire
John E. Strobeck, MD, PhD
Director of the Heart-Lung Associates of America
